ABSTRACT
Epirubicin hydrochloride injection is indicated as a therapy for patients with primary breast cancer. This drug has been reclassified as a drug with high emetic potential according to the American Society of Clinical Oncology Guidelines for Antiemetics in Oncology. Therefore, patients who receive this agent should also receive fosaprepitant dimeglumine, an anti-emetic agent. However, it has been reported that fosaprepitant induces vascular pain when used in anthracycline-based regimens administered via the peripheral veins. In order to relieve the fosaprepitant and epirubicin-induced vascular pain associated with vasculitis, dexamethasone was administered at the onset of vascular pain. There is a possibility that the fosaprepitant and epirubicin-induced pain may improve owing to the administration of dexamethasone; however, further trials are required to confirm the effect of this method.
Subject(s)
Antiemetics/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Dexamethasone/therapeutic use , Pain/prevention & control , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Epirubicin/administration & dosage , Epirubicin/adverse effects , Humans , Middle Aged , Morpholines/administration & dosage , Morpholines/adverse effects , Pain/chemically induced , Vomiting/chemically induced , Vomiting/prevention & control , Young AdultABSTRACT
Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent non-small cell lung cancer(NSCLC)patients. These drugs are known to cause a skin rash, one of the major side effects, at a high frequency. Biotin is a water-soluble vitamin, andit belongs to the vitamin B family. It is well known that biotin deficiency increases the risk of skin dermatitis. We administered biotin to four patients with skin rash, all of whom were treatedwith either gefitinib or erlotinib andwere unable to be treatedby a steroid ointment alone. In all patients, administration of biotin reduced the skin rash. Surprisingly, in 2 patients in whom EGFR-TKI therapy was discontinued because of the skin rash, the administration of biotin allowed for long-term gefitinib or erlotinib treatment. Biotin may be considereduseful for the treatment of skin rash causedby EGFR-TKIs. Further trials may be needed to confirm the value of biotin in this setting.
Subject(s)
Antineoplastic Agents/adverse effects , Biotin/therapeutic use , Erythema/drug therapy , Protein Kinase Inhibitors/adverse effects , Quinazolines/adverse effects , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Erlotinib Hydrochloride , Erythema/chemically induced , Female , Gefitinib , Humans , Lung Neoplasms/drug therapy , Male , Prospective Studies , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic useABSTRACT
Agents used in cancer treatment can cause many side effects in patients. Oxaliplatin is a platinum-based cytotoxic agent that is used in the treatment of colorectal cancers, and one of its potential side effects is vascular pain. The current article will discuss the coadministration of dexamethasone and its potential effect on oxaliplatin-related vascular pain.
Subject(s)
Antineoplastic Agents/administration & dosage , Dexamethasone/administration & dosage , Glucose/administration & dosage , Organoplatinum Compounds/administration & dosage , Pain/drug therapy , Vascular Diseases/drug therapy , Antineoplastic Agents/adverse effects , Colorectal Neoplasms/drug therapy , Humans , Organoplatinum Compounds/adverse effects , Oxaliplatin , Pain/chemically induced , Vascular Diseases/chemically inducedABSTRACT
In the present study, we investigated the effect of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test after the administration of selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor. Single and repeated administration of selegiline significantly decreased the duration of immobility in normal rats. When selegiline was administered for 15 days, we observed a significant decrease in immobility in rats treated with ACTH for 14 days. The immobility-decreasing effect of selegiline was blocked by nafadotride, a selective dopamine D(3)-receptor antagonist in normal and ACTH-treated rats. Selegiline may be useful in an animal model of depressive conditions resistant to tricyclic antidepressant treatment via the dopamine D(3) receptor.
Subject(s)
Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Cosyntropin/pharmacology , Monoamine Oxidase Inhibitors/pharmacology , Selegiline/pharmacology , Animals , Benzazepines/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Models, Animal , Motor Activity/drug effects , Naphthalenes/pharmacology , Pyrrolidines/pharmacology , Rats , Rats, Wistar , Receptors, Dopamine D3/drug effects , Swimming , Time FactorsABSTRACT
We examined the influence of imipramine, a traditional tricyclic antidepressant, on the binding to serotonin (5-HT)(2) receptors and levels of 5-HT(2A)-receptor mRNA in the frontal cortex of rats treated with adrenocorticotropic hormone (ACTH). Chronic treatment with ACTH significantly increased the binding of [(3)H]-ketanserin to 5-HT(2) receptors and the expression of 5-HT(2A)-receptor mRNA in the frontal cortex. However, it did not alter the concentration of 5-HT or 5-hydroxyindole acetic acid. The effect of chronic ACTH treatment on 5-HT(2) receptor and 5-HT(2A)-receptor mRNA levels was not altered by the chronic administration of imipramine. Also, imipramine did not affect the hyperfunction of 5-HT(2A) receptors caused by chronic ACTH treatment. These findings suggest that chronic treatment with ACTH acts to increase 5-HT(2A)-receptor synthesis through increased gene transcription, without modulating presynaptic serotonergic neurotransmission.
